Clinical Trial Update: A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients [Phase 3]

View source ↗

Summary

Phase 3 study completion for TVP-1012 (1 mg) in early Parkinson's disease; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• TVP-1012

Snippet

Sponsor: Takeda | Conditions: Parkinson's Disease | Phase 3 | Status: COMPLETED | Results posted: 2018-12-31